These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6467458)

  • 1. Radioimmunoassay for clebopride, a new benzamide drug with antidopaminergic activity.
    Yano M; Nakamichi K; Yamaki T; Fukami T; Ishikawa K; Matsumoto I
    Chem Pharm Bull (Tokyo); 1984 Apr; 32(4):1491-7. PubMed ID: 6467458
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac repolarization.
    Kim KS; Shin WH; Park SJ; Kim EJ
    Int J Toxicol; 2007; 26(1):25-31. PubMed ID: 17365143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [On the induction of gastric emptying by clebopride and other antidopaminergic drugs].
    Llupiá J; Roberts DJ
    Arch Farmacol Toxicol; 1979 Dec; 5(3):147-9. PubMed ID: 546330
    [No Abstract]   [Full Text] [Related]  

  • 4. [Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System].
    Cuena Boy R; Maciá Martínez MA
    Aten Primaria; 1998 Mar; 21(5):289-95. PubMed ID: 9608114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antagonism of pre- and postsynaptic dopamine receptors by clebopride and related orthopramides].
    Berga P; Beckett PR; Roberts DJ
    Arch Farmacol Toxicol; 1979 Dec; 5(3):144-6. PubMed ID: 546329
    [No Abstract]   [Full Text] [Related]  

  • 6. High-performance liquid chromatographic determination of a new benzamide in biological fluids for use in a human pharmacokinetic study.
    Bressolle F; Bres J; Snoussi M
    J Chromatogr; 1985 Oct; 343(2):443-8. PubMed ID: 4066886
    [No Abstract]   [Full Text] [Related]  

  • 7. An estimate of the risk of movement disorders associated with the chronic use of clebopride.
    Sempere AP; Duarte J; García F; Cabezas C; Coria F; Clavería LE
    Mov Disord; 1996 Sep; 11(5):582-3. PubMed ID: 8866504
    [No Abstract]   [Full Text] [Related]  

  • 8. High-performance liquid chromatographic measurement of (R)-4-[3-[(2-hydroxy-2-phenethyl)amino]-3-methylbutyl]benzamide monohydrochloride (LY195448) and its p-hydroxy metabolite in human plasma and urine.
    Engineer MS; Newman RA
    J Chromatogr; 1990 May; 527(2):473-80. PubMed ID: 2387891
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of clebopride in plasma by capillary gas chromatography-negative-ion chemical ionization mass spectrometry.
    Robinson PR; Jones MD; Maddock J
    J Chromatogr; 1988 Nov; 432():153-63. PubMed ID: 3220885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of long-term treatment of the rat with clebopride on the morphology of the mammary gland.
    de Lima TC; Morato GS; Loch S; Tames DR
    Pharmacology; 1990; 40(1):54-9. PubMed ID: 2330385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clebopride, a new orthopramide with potent and selective central antidopaminergic properties].
    Roberts DJ; Salazar W; Beckett PR; Nahorski SR
    Arch Farmacol Toxicol; 1978 Apr; 4(1):102-4. PubMed ID: 100059
    [No Abstract]   [Full Text] [Related]  

  • 12. Clebopride enhances contractility of the guinea pig stomach by blocking peripheral D2 dopamine receptor and alpha-2 adrenoceptor.
    Takeda K; Taniyama K; Kuno T; Sano I; Ishikawa T; Ohmura I; Tanaka C
    J Pharmacol Exp Ther; 1991 May; 257(2):806-11. PubMed ID: 1851838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical therapy of gastroesophageal reflux. Evaluation of the activity of clebopride by continuous intraluminal pH measurement].
    Alvisi V; Onofrio W; Intrieri L; D'Ambrosi A
    Minerva Med; 1987 Oct; 78(19):1421-6. PubMed ID: 3670685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of clebopride and a major metabolite N-desbenzylclebopride in plasma by capillary gas chromatography-negative-ion chemical ionization mass spectrometry.
    Robinson PR; Jones MD; Maddock J; Rees LW
    J Chromatogr; 1991 Mar; 564(1):147-61. PubMed ID: 1860909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of the gastric antisecretory activity of histamine H2-receptor antagonists by clebopride.
    Fernández AG; Massingham R; Roberts DJ
    Methods Find Exp Clin Pharmacol; 1988 May; 10(5):285-93. PubMed ID: 2899659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of clebopride and its metabolites in rat blood by acid decomposition.
    Hayasaka Y; Murata S; Umemura K
    Chem Pharm Bull (Tokyo); 1981 May; 29(5):1478-80. PubMed ID: 7296713
    [No Abstract]   [Full Text] [Related]  

  • 17. Progressive supranuclear palsy syndrome induced by clebopride.
    Campdelacreu J; Kumru H; Tolosa E; Valls-Solé J; Benabarre A
    Mov Disord; 2004 Apr; 19(4):482-4. PubMed ID: 15077251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic conjugation and blood levels of clebopride in the rabbit.
    Segura J; Borja L; García I
    Arch Farmacol Toxicol; 1981 Aug; 7(2):277-82. PubMed ID: 7332367
    [No Abstract]   [Full Text] [Related]  

  • 19. [Acute familial dystonia caused by antidopaminergic drugs].
    Hernández J; Arés A; Cantarero S; García Ruiz PJ
    Neurologia; 1999 Jan; 14(1):45. PubMed ID: 10079694
    [No Abstract]   [Full Text] [Related]  

  • 20. [Structural study of substituted benzamides with antidopaminergic D-2 activity. Comparison with orthopramides with 5HT-3 antiserotoninergic profile].
    Collin S
    J Pharm Belg; 1991; 46(1):55-66. PubMed ID: 1828834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.